Table 6.
Ranking score | HIVPR | FXa | DHFR | FGFr1 | P38 MAP | ADA | ER | AmpC | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AUC | D%a | AUC | D%a | AUC | D%a | AUC | D%a | AUC | D%a | AUC | D%a | AUC | D%a | AUC | D%a | |
RMSD | 0.78 | - | 0.91 | - | 0.79 | - | 0.55 | - | 0.57 | - | 0.80 | - | 0.81 | - | 0.70 | - |
SP LGFE | 0.54 | 4 | 0.78 | 8 | 0.67 | 9 | 0.75 | 14 | 0.75 | 43 | 0.58 | 4 | 0.86 | 46 | 0.55 | 0 |
MC LGFE | 0.49 | 2 | 0.90 | 17 | 0.70 | 6 | 0.66 | 13 | 0.73 | 30 | 0.64 | 0 | 0.83 | 41 | 0.62 | 0 |
D%=Ndiff/Nligands*100%, where Ndiff is the number of active ligands identified by LGFE score among the top 10% LGFE ranked compounds that are not found by RMSD score among the top 10% RMSD ranked compounds, and Nligands are the total number of active ligands in the database for the target.